{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T07:42:50Z","timestamp":1649058170095},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1007\/s11940-007-0030-5","type":"journal-article","created":{"date-parts":[[2008,3,18]],"date-time":"2008-03-18T14:10:59Z","timestamp":1205849459000},"page":"48-54","source":"Crossref","is-referenced-by-count":0,"title":["Optic neuritis: The role of disease-modifying therapy disease-modifying therapy in this clinically isolated syndrome"],"prefix":"10.1007","volume":"9","author":[{"given":"Fiona","family":"Costello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,19]]},"reference":[{"key":"30_CR1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00415-005-0655-9","volume":"252","author":"P. Nilsson","year":"2005","unstructured":"Nilsson P, Larsson EM, Maly-Sundgren P, et al.: Predicting the outcome of optic neuritis\u2014evaluation of risk factors after 30 years of follow up. J Neurol 2005, 252:396\u2013402.","journal-title":"J Neurol"},{"key":"30_CR2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0420.2001.790302.x","volume":"79","author":"M. Soderstrom","year":"2001","unstructured":"Soderstrom M: Optic neuritis and multiple sclerosis. Acta Ophthalmol Scand 2001, 79:223\u2013227.","journal-title":"Acta Ophthalmol Scand"},{"key":"30_CR3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1474-4422(05)70071-5","volume":"4","author":"D. Miller","year":"2005","unstructured":"Miller D, Barkhof F, Montalban X, et al.: Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis and prognosis. Lancet Neurol 2005, 4:281\u2013288.","journal-title":"Lancet Neurol"},{"key":"30_CR4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(05)00992-0","volume":"4","author":"E.M. Frohman","year":"2005","unstructured":"Frohman EM, Frohman TC, Zee DS, et al.: The neuroophthalmology of multiple sclerosis. Lancet Neurol 2005, 4:111\u2013121.","journal-title":"Lancet Neurol"},{"key":"30_CR5","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(02)11919-2","volume":"360","author":"S.J. Hickman","year":"2002","unstructured":"Hickman SJ, Dalton CM, Miller DH: Management of acute optic neuritis. Lancet 2002, 360:1953\u20131962.","journal-title":"Lancet"},{"key":"30_CR6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1212\/WNL.50.3.708","volume":"50","author":"M. Soderstrom","year":"1998","unstructured":"Soderstrom M, Ya-Ping J, Hillert J: Optic neuritis prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998, 50:708\u2013714.","journal-title":"Neurology"},{"key":"30_CR7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/s-2002-36534","volume":"22","author":"B.A.C. Cree","year":"2002","unstructured":"Cree BAC, Goodin DS, Hauser SL: Neuromyelitis optica. Semin Neurol 2002, 22:105\u2013122.","journal-title":"Semin Neurol"},{"key":"30_CR8","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"354","author":"V.A. Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, et al.: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 354:2106\u20132112.","journal-title":"Lancet"},{"key":"30_CR9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"D.M. Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG: The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 1999, 53:1107\u20131114.","journal-title":"Neurology"},{"key":"30_CR10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1212\/WNL.38.9.1353","volume":"38","author":"D.J. Macfayden","year":"1988","unstructured":"Macfayden DJ, Drance SM, Douglas GR, et al.: The retinal nerve fiber layer, neuroretinal rim area, and visual evoked potential in MS. Neurology 1988, 38:1353\u20131358.","journal-title":"Neurology"},{"key":"30_CR11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1167\/iovs.03-1213","volume":"4","author":"D. Sisto","year":"2005","unstructured":"Sisto D, Trojano M, Vetrugno M, et al.: Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. Invest Ophthalmol Vis Sci 2005, 4:1264\u20131268.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"30_CR12","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/00207450490461332","volume":"114","author":"G. Acar","year":"2004","unstructured":"Acar G, Ozakbas S, Cakmakci H, et al.: Visual evoked potential is superior to triple dose magnetic resonance imaging in the diagnosis of optic nerve involvement. Int J Neurosci 2004, 114:1025\u20131033.","journal-title":"Int J Neurosci"},{"key":"30_CR13","first-page":"4032","volume":"41","author":"D.C. Hood","year":"2000","unstructured":"Hood DC, Odel JG, Zhang X: Tracking the recovery of local optic nerve function after optic neuritis: a multifocal VEP study. Invest Ophthalmol Vis Sci 2000, 41:4032\u20134038.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"30_CR14","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0022-510X(99)00273-7","volume":"172","author":"J.H. Simon","year":"2000","unstructured":"Simon JH, McDonald WI: Assessment of optic nerve damage in multiple sclerosis using magnetic resonance imaging. J Neurol Sci 2000, 172:S23\u2013S26.","journal-title":"J Neurol Sci"},{"key":"30_CR15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1474-4422(05)70095-8","volume":"4","author":"D. Miller","year":"2005","unstructured":"Miller D, Barkhof F, Montalban X, et al.: Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol 2005, 4:341\u2013348.","journal-title":"Lancet Neurol"},{"key":"30_CR16","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1093\/brain\/awh284","volume":"127","author":"S.J. Hickman","year":"2004","unstructured":"Hickman SJ, Toosy AT, Jones SJ, et al.: A serial MRI study following optic nerve mean area in acute optic neuritis. Brain 2004, 127:2498\u20132505.","journal-title":"Brain"},{"key":"30_CR17","first-page":"73","volume":"14","author":"E.R. Eggenberger","year":"2001","unstructured":"Eggenberger ER: Inflammatory optic neuropathies. Ophthalmol Clin North Am 2001, 14:73\u201382.","journal-title":"Ophthalmol Clin North Am"},{"key":"30_CR18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.49.5.1404","volume":"49","author":"Optic Neuritis Study Group","year":"1997","unstructured":"Optic Neuritis Study Group: The five-year risk of multiple sclerosis after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology 1997, 49:1404\u20131413.","journal-title":"Neurology"},{"key":"30_CR19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/archopht.121.7.944","volume":"121","author":"Optic Neuritis Study Group","year":"2003","unstructured":"Optic Neuritis Study Group: High and low risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Arch Ophthalmol 2003, 121:944\u2013949.","journal-title":"Arch Ophthalmol"},{"key":"30_CR20","first-page":"2520","volume":"40","author":"V. Parisi","year":"1999","unstructured":"Parisi V, Manni G, Spadaro M, et al.: Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci 1999, 40:2520\u20132527.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"30_CR21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ana.20575","volume":"58","author":"S.A. Trip","year":"2005","unstructured":"Trip SA, Schlottmann PG, Jones SJ, et al.: Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005, 58:383\u2013391.","journal-title":"Ann Neurol"},{"key":"30_CR22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ophtha.2005.10.040","volume":"113","author":"J.B. Fisher","year":"2006","unstructured":"Fisher JB, Jacobs DA, Markowitz CE, et al.: Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006, 113:324\u2013332.","journal-title":"Ophthalmology"},{"key":"30_CR23","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.20851","volume":"59","author":"F. Costello","year":"2006","unstructured":"Costello F, Coupland S, Hodge W, et al.: Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006, 59:963\u2013969.","journal-title":"Ann Neurol"},{"key":"30_CR24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"R.W. Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM: A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326:581\u2013588.","journal-title":"N Engl J Med"},{"key":"30_CR25","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","volume":"109","author":"Optic Neuritis Study Group","year":"1991","unstructured":"Optic Neuritis Study Group: The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991, 109:1673\u20131678.","journal-title":"Arch Ophthalmol"},{"key":"30_CR26","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00055735-200112000-00004","volume":"12","author":"G.P. Stavern Van","year":"2001","unstructured":"Van Stavern GP: Management of optic neuritis and multiple sclerosis. Curr Opin Ophthalmol 2001, 12:400\u2013407.","journal-title":"Curr Opin Ophthalmol"},{"key":"30_CR27","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1212\/WNL.54.11.2039","volume":"54","author":"D.I. Kaufman","year":"2000","unstructured":"Kaufman DI, Trobe JD, Eggenberger ER: Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology 2000, 54:2039\u20132044.","journal-title":"Neurology"},{"key":"30_CR28","first-page":"1386","volume":"9","author":"R.W. Beck","year":"2004","unstructured":"Beck RW, Smith CH, Gal RL et al.: Neurologic impairment 10 years after optic neuritis. Arch Neurol 2004, 9:1386\u20131389.","journal-title":"Arch Neurol"},{"key":"30_CR29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","volume":"343","author":"L.D. Jacobs","year":"2000","unstructured":"Jacobs LD, Beck RW, Simon JH: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000, 343:898\u2013904.","journal-title":"N Engl J Med"},{"key":"30_CR30","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","volume":"357","author":"G. Comi","year":"2001","unstructured":"Comi G, Filippi M, Barkof F: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001, 357:1576\u20131582.","journal-title":"Lancet"},{"key":"30_CR31","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","volume":"67","author":"L. Kappos","year":"2006","unstructured":"Kappos L, Polman CH, Freedman MS, et al.: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242\u20131249.","journal-title":"Neurology"},{"key":"30_CR32","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/archneur.63.4.614","volume":"63","author":"E.M. Frohman","year":"2006","unstructured":"Frohman EM, Havrdova E, Lublin F, et al.: Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 2006, 63:614\u2013619.","journal-title":"Arch Neurol"},{"key":"30_CR33","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/archneur.63.4.611","volume":"63","author":"S.J. Pittock","year":"2006","unstructured":"Pittock SJ, Weinshenker BG, Noseworthy JH, et al.: Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 2006, 63:611\u2013614.","journal-title":"Arch Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-007-0030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-007-0030-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-007-0030-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:51Z","timestamp":1559437011000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-007-0030-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["30"],"URL":"https:\/\/doi.org\/10.1007\/s11940-007-0030-5","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}